Ikarian Capital’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Ikarian Capital’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-283,464	Closed	-$130K	–	180
2023 Q2	$130K	Hold	283,464	–	–	0.02%	116
2023 Q1	$6.56M	Hold	283,464	–	–	1.49%	21
2022 Q4	$0	Hold	283,464	–	–	﹤0.01%	114
2022 Q3	$0	Sell	283,464 -48,831	-15%	-$979K	﹤0.01%	175
2022 Q2	$0	Buy	+332,295	New	+$5.22M	﹤0.01%	219
2020 Q3	–	Sell	-673,995	Closed	-$7.79M	–	222
2020 Q2	$7.79M	Sell	673,995 -53,605	-7%	-$739K	0.62%	51
2020 Q1	$9.97M	Buy	727,600 +359,894	+98%	+$4.26M	0.75%	36
2019 Q4	$2.17M	Buy	+367,706	New	+$2M	0.35%	62

Ikarian Capital's KDNY Position: Q3 2023 in Review

Ikarian Capital sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 283,464 shares — an estimated $130K sold.

Ikarian Capital first reported a position in KDNY in Q4 2019 and held it in 8 quarters. The position peaked at $9.97M in Q1 2020. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Ikarian Capital reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Ikarian Capital sold 283,464 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $130K.
Ikarian Capital first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2019 and held it in 8 quarters.
Ikarian Capital's Chinook Therapeutics, Inc. Common Stock position peaked at $9.97M in Q1 2020.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Ikarian Capital's 13F filing for Q3 2023, filed 14 Nov 2023.